Birch Pollen Allergy – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Birch Pollen Allergy – Pipeline Review, H1 2019’, provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy

– The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects

– The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Desentum Oy

HAL Allergy BV

Laboratorios LETI SL

S-TARget therapeutics GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Birch Pollen Allergy - Overview

Birch Pollen Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Birch Pollen Allergy - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Birch Pollen Allergy - Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Desentum Oy

HAL Allergy BV

Laboratorios LETI SL

S-TARget therapeutics GmbH

Birch Pollen Allergy - Drug Profiles

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birch pollen allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-31 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Birch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SG-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Birch Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccines For Birch Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Birch Pollen Allergy - Dormant Projects

Birch Pollen Allergy - Discontinued Products

Birch Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Dec 13, 2018: Anergis reports positive preclinical proof-of concept data of the Second-Generation COP Allergy Vaccine

Sep 05, 2018: Anergis initiates development of second-generation COP Allergy Vaccines; announces publication of sustained efficacy data from Ph. IIb study follow-Up

Aug 14, 2018: HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany

May 27, 2018: Allergy experts: Clinical effect of ALK's tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials

Jun 14, 2017: Desentum has two presentations in EAACI 2017

May 10, 2017: Desentum is preparing to start clinical trials with birch pollen allergy vaccine

Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study

May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy

May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis

Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria

Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen

May 12, 2013: Desentum: EARTO innovation prize to VTT

Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomay´s Bet v 1

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Birch Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Birch Pollen Allergy – Pipeline by ALK-Abello AS, H1 2019

Birch Pollen Allergy – Pipeline by Allergy Therapeutics Plc, H1 2019

Birch Pollen Allergy – Pipeline by Anergis SA, H1 2019

Birch Pollen Allergy – Pipeline by Biomay AG, H1 2019

Birch Pollen Allergy – Pipeline by Desentum Oy, H1 2019

Birch Pollen Allergy – Pipeline by HAL Allergy BV, H1 2019

Birch Pollen Allergy – Pipeline by Laboratorios LETI SL, H1 2019

Birch Pollen Allergy – Pipeline by S-TARget therapeutics GmbH, H1 2019

Birch Pollen Allergy – Dormant Projects, H1 2019

Birch Pollen Allergy – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Birch Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports